Healthcare Microcap Pops On DSMB Recommendation

By: Tomas Ronolski - AllPennyStocks.com News

Wednesday, December 21, 2022

A New Jersey-based healthcare company captured the attention of the trading community on Wednesday after it was announced that it has received the recommendation from the independent Data and Safety Monitoring Board (DSMB) to continue the pivotal Safe and Timely Antithrombotic Removal – Ticagrelor ( STAR-T ) trial as planned without any modifications, according to the release.

This sent shares of CytoSorbents Corporation (Nasdaq:CTSO) soaring on the news as traders pushed the price up to $1.20/share (+16.50%) at the session high.

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany.

Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.